1126422-86-3

Upstream product

• 163105-90-6 2-methoxypyridin-3-yl-boronic acid 
• 16382-17-5 5-ethoxy-indole-2-carboxylic acid ethyl ester 
• 1354330-55-4 C₁₃H₁₄INO₃ 
• 1354330-65-6 C₁₉H₂₀N₂O₄ 
• 1126422-65-8 1-(2,5-difluoro-benzyl)-5-hydroxy-3-(2-methoxy-pyridin-3-yl)-1H-indole-2-carboxylic acid ethyl ester 
• 75-03-6 ethyl iodide 

Downstream Products

• 1126422-88-5 C₂₄H₂₀F₂N₂O₄ 
• 1130801-86-3 1-[(2,5-difluorophenyl)methyl]-3-(1,2-dihydro-2-oxo-3-pyridinyl)-5-ethoxy-1H-indole-2-carboxylic acid 
• 1354330-89-4 C₂₅H₂₂F₂N₂O₄ 

Relevant academic research and scientific papers

Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the Hepatitis C Virus (HCV) NS5B polymerase

Starting with the indole-based C-3 pyridone lead HCV polymerase inhibitor 2, extensive SAR studies were performed at different positions of the indole core. The best C-5 groups were found to be compact and nonpolar moieties and that the C-6 attachments were not affecting potency. Limited N-1 benzyl-type substituent studies indicated that the best substitutions were fluoro or methyl groups at 2′ or 5′ positions of the benzyl group. To improve pharmacokinetic (PK) properties, acylsulfonamides were incorporated as acid isosteres at the C-2 position. Further optimization of the combination at N-1, C-2, C-5, and C-6 resulted in the identification of compound 56, which had an excellent potency in both NS5B enzyme (IC50 = 0.008 μM) and cell-based replicon (EC50 = 0.02 μM) assays and a good oral PK profile with area-under-the curve (AUC) of 14 and 8 μM?h in rats and dogs, respectively. X-ray structure of inhibitor 56 bound to the enzyme was also reported.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.